MENU
ALT
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Altimmune (ALT) Earnings Date & Reports

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases... Show more

A.I. Advisor
published Earnings

ALT is expected to report earnings to rise 3.80% to -15 cents per share on March 03

Altimmune ALT Stock Earnings Reports
Q4'26
Est.
$-0.16
Q3'26
Missed
by $0.01
Q2'26
Beat
by $0.03
Q1'26
Beat
by $0.06
Q4'25
Missed
by $0.02
The last earnings report on November 12 showed earnings per share of -15 cents, missing the estimate of -14 cents. With 4.05M shares outstanding, the current market capitalization sits at 404.60M.
A.I.Advisor
Nov 06, 2026

Altimmune (ALT) Earnings Preview: Clinical Readouts Loom as Losses Stay in Focus

Key Takeaways

  • Altimmune (NASDAQ: ALT) is scheduled to report its third quarter 2026 financial results on Thursday, November 12, 2026, before the market opens, with a conference call at 8:30 a.m. ET.
  • Wall Street consensus calls for a net loss of approximately $0.14 per share, versus a loss of $0.21 per share in the same quarter a year earlier.
  • The company beat consensus earnings-per-share estimates in seven of its last eight quarters, including its second quarter 2026 report in August.
  • As a clinical-stage biopharmaceutical company, Altimmune generates minimal revenue, so investor attention will center on cash runway, spending trends, and pipeline updates for its lead candidate pemvidutide.
  • Key catalysts include the Phase III PERFORMA trial in MASH (metabolic dysfunction-associated steatohepatitis), the Phase II RECLAIM study in AUD (alcohol use disorder), and the RESTORE study in ALD (alcohol-associated liver disease).
  • For more context on this ticker, explore Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
  • You can also explore Trending AI Robots to see AI-driven trading strategies across the broader market.

Earnings Context and Why It Matters

Altimmune is a late-stage biopharmaceutical company developing pemvidutide, an investigational balanced 1:1 glucagon/GLP-1 (glucagon-like peptide-1) receptor agonist for serious liver diseases. Because the company is pre-revenue and pre-profit, its quarterly earnings releases are less about top-line sales and more about capital efficiency, operating expense trends, and clinical execution. The November 12 report arrives at a pivotal moment: Altimmune recently launched the global Phase III PERFORMA trial in MASH and reported positive Phase II RECLAIM data in alcohol use disorder. With roughly $519 million in cash reported as of June 30, 2026, investors will be watching closely whether management reaffirms its runway guidance through the anticipated 2029 MASH readout.

Earnings Expectations

Analysts expect Altimmune to report a net loss of approximately $0.14 per share for the third quarter of 2026, a narrowing from the $0.21 per-share loss recorded in the third quarter of 2025. Revenue expectations are negligible, with consensus estimates in the low single-digit thousands of dollars, reflecting the company's development-stage status. In the most recent quarter, Altimmune posted a loss of $0.12 per share, beating the $0.14 consensus estimate, and the company has exceeded EPS estimates in seven of its last eight quarters. Heading into this report, investors will focus on research and development (R&D) expense growth, general and administrative (G&A) costs, and any updated commentary on enrollment timelines for the PERFORMA and RESTORE trials.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, making it a practical resource for those monitoring earnings-driven moves in the biotechnology sector.

Market Reaction and Investor Sentiment

Sentiment heading into Altimmune's third quarter 2026 report reflects a mix of enthusiasm around its clinical pipeline and caution over ongoing cash burn. The stock has traded well below its 52-week high, and analysts' price targets remain far above the current share price, highlighting the gap between clinical upside potential and near-term execution risk. Short interest remains elevated, which can amplify volatility around binary news events. With no meaningful revenue to anchor expectations, the market's reaction will likely hinge on expense discipline, any updates to trial timelines, and whether management signals progress on regulatory pathways for pemvidutide in alcohol use disorder.

Forward Outlook and Key Factors to Monitor

Following the November 12 report, investors should watch several forward-looking developments. First, enrollment progress in the Phase III PERFORMA trial in MASH is critical; management has targeted an 18-to-24-month enrollment window across roughly 290 to 300 global sites, with a 52-week biopsy readout expected in 2029.

Second, the regulatory path in alcohol use disorder will be in focus. Altimmune has indicated plans to request an end-of-Phase II meeting with the FDA (U.S. Food and Drug Administration) to discuss a potential pivotal study, and any clarity on trial design or funding strategy could move sentiment. Management has expressed a preference for non-dilutive funding for a possible AUD Phase III trial.

Third, cash runway remains a central theme. The company's ability to fund operations through the PERFORMA readout without additional equity financing will be closely scrutinized, particularly as R&D and G&A costs trend higher.

Finally, top-line data from the RESTORE study in alcohol-associated liver disease, expected in the second half of 2027, represents the next major clinical catalyst on the horizon.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of biopharmaceuticals

Industry Biotechnology

Industry
Miscellaneous Commercial Services
Address
910 Clopper Road
Phone
+1 240 654-1450
Employees
57
Web
https://www.altimmune.com